Catastrophic antiphospholipid syndrome: A rare cause of disseminated microvascular thrombotic injury – a case report with pathological and molecular correlative studies

Catastrophic antiphospholipid syndrome (CAPS) is a severe and rare variant of antiphospholipid syndrome (APS) characterized by acute multiorgan failure due to small vessel thrombi in patients with positive antiphospholipid antibodies. We report a fatal case of catastrophic antiphospholipid syndrome in a young woman with a history of polymyositis and Hodgkin lymphoma. The patient was admitted to hospital because of severe foot pain following several weeks of skin ulcerations. Doppler ultrasonography showed evidence of arterial ischemia of the both lower extremities. Despite anticoagulation, immunosuppression, plasmapheresis and antibiotic therapy, she developed cutaneous gangrene, retroperitoneal hematoma, ileus, and acute respiratory and renal failure that resulted in death. Autopsy showed multifocal vascular injury and microthrombi with associated hemorrhages and infarcts in multiple organs. The patient had normal levels of functional protein C and protein S and a normal level of plasma homocysteine. Tests for common thromophilic gene mutations including prothrombin 20210, factor V Leiden 1691, and methylene tetrahydrofolate reductase 677 were negative. To our knowledge, this is the first CAPS patient with molecular studies for genetic prothrombotic mutations. Our report showed that there was no association between the development of CAPS and inherited thromophilia.

[1]  M. García-Carrasco,et al.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients , 2004, Annals of the rheumatic diseases.

[2]  R. Cervera,et al.  Catastrophic antiphospholipid syndrome: where do we stand? , 2003, Arthritis and rheumatism.

[3]  Y. Shoenfeld,et al.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines , 2003, Lupus.

[4]  M. Laposata,et al.  Antiphospholipid antibody syndrome in a six-year-old female patient. , 2003, American journal of ophthalmology.

[5]  R. Asherson,et al.  Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. , 2002, The Journal of rheumatology.

[6]  C. Yamashiro,et al.  Extraction and Amplification of DNA From Formalin-Fixed, Paraffin-Embedded Tissues , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  J. Rauch,et al.  Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. , 2002, The Journal of rheumatology.

[8]  P. Meroni,et al.  Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. , 2002, Autoimmunity reviews.

[9]  M. Vaphiades,et al.  Catastrophic antiphospholipid antibody syndrome manifesting as an orbital ischemic syndrome. , 2001, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[10]  M. Petri,et al.  Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients , 2001, Medicine.

[11]  R. Bick.  State-of-the-Art Review: Antiphospholipid Thrombosis Syndromes , 2001 .

[12]  R. Ware,et al.  Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus. , 2001, The Journal of rheumatology.

[13]  S. Bydlowski,et al.  Detection of methylenetetrahydrofolate reductase (MTHFR) C677T and prothrombin G20210A mutations: second restriction site for digestion control of PCR products. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[14]  T. Nishino,et al.  Catastrophic antiphospholipid antibody syndrome in systemic lupus erythematosus: an autopsy case report of a young woman. , 2000, Internal medicine.

[15]  A. Gharavi,et al.  New developments in viral peptides and APL induction. , 2000, Journal of autoimmunity.

[16]  M. Amigo,et al.  Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: Relationship to pathogenesis , 2000, Current rheumatology reports.

[17]  M. Moia,et al.  The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants , 2000, British journal of haematology.

[18]  Y. Shoenfeld,et al.  Dermatomyositis and polymyositis associated with the antiphospholipid syndrome—a novel overlap syndrome , 2000, Lupus.

[19]  H. Chaimovich,et al.  Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides , 1999, Lupus.

[20]  M. Zilberman,et al.  Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration. , 1998, The Journal of laboratory and clinical medicine.

[21]  R. Bertina,et al.  Laboratory Diagnosis of APC-Resistance: A Critical Evaluation of the Test and the Development of Diagnostic Criteria , 1994, Thrombosis and Haemostasis.

[22]  J. Batlle,et al.  Prevalence, Follow-Up and Clinical Significance of the Anticardiolipin Antibodies in Normal Subjects , 1994, Thrombosis and Haemostasis.

[23]  T. Ozcelik,et al.  Survey of Factor V Leiden and Prothrombin Gene Mutations in Systemic Lupus Erythematosus , 2001, Clinical Rheumatology.

[24]  Shames Ds,et al.  Catastrophic antiphospholipid antibody syndrome. , 2001, Connecticut medicine.

[25]  O. Olopade,et al.  Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: β2‐glycoprotein I antibodies as a marker of response to therapy , 1999, Journal of clinical apheresis.